Novavax To Evaluate Swine Flu Vaccine


Novavax Inc. (Nasdaq: NVAX) will work with the National Institutes of Health to evaluate a virus-like particle vaccine against the swine flu, influenza A (H1N1), virus. Shares of the biopharmaceutical jumped $1.00 to $2.87.

About this Entry

This page contains a single entry by published on June 4, 2009 10:23 AM.

Intel Offers $884 Million For Wind River was the previous entry in this blog.

KeyCorp Upgraded is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Powered by Movable Type 5.12